LEXICON PHARMACEUTICALS, INC. Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)
LEXICON PHARMACEUTICALS, INC. (LXRX) reported Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-03.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill · last filed 2023-03-03
- LEXICON PHARMACEUTICALS, INC. impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2019-12-31 was -$28.64M.
- LEXICON PHARMACEUTICALS, INC. impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2019-09-30 was $28.64M.
- LEXICON PHARMACEUTICALS, INC. impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2018-12-31 was $0.00.
- LEXICON PHARMACEUTICALS, INC. impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2018-09-30 was $0.00.
- LEXICON PHARMACEUTICALS, INC. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2022 was $0.00.
- LEXICON PHARMACEUTICALS, INC. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- LEXICON PHARMACEUTICALS, INC. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2020 was $1.60M.
- LEXICON PHARMACEUTICALS, INC. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2019 was $0.00.
| Period end | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 3 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 6 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 9 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 12 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 12 month as first filed |
|---|---|---|---|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-03-03 | ||||
| 2021-12-31 | $0.00 10-K · filed 2023-03-03 | ||||
| 2020-12-31 | $1.60M 10-K · filed 2023-03-03 | ||||
| 2019-12-31 | -$28.64M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $0.00 derived: sum of 2 quarters · filed 2022-03-10 | $0.00 10-K · filed 2022-03-10 | $28.64M 10-K · filed 2020-03-12 | |
| 2019-09-30 | $28.64M 10-Q · filed 2019-11-07 | $28.64M 10-Q · filed 2019-11-07 | |||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | $0.00 derived: sum of 2 quarters · filed 2021-03-12 | $0.00 10-K · filed 2021-03-12 | ||
| 2018-09-30 | $0.00 10-Q · filed 2019-11-07 | $0.00 10-Q · filed 2019-11-07 | |||
| 2017-12-31 | $0.00 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |